drugset / Trial / NCT02523300

Glucocorticoid on the Prognosis of TEVAR

NCT02523300

Unknown 240 enrolled Changhai Hospital
RandomizedParallel-groupOpen-labelPrevention

Summary

To explore the potential prognostic effect of glucocorticoid on the postoperative aorta-related adverse events after aortic dissections patients underwent thoracic endovascular aortic repair (TEVAR), glucocorticoid (30mg/kg) will be intravenously given within 2h after TEVAR.

Timeline

Start
2015-10
Primary completion
2017-09
Completion
2019-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Prednisolone Other / unclassified 30 mg/kg Intravenous

Indications